Dover has entered right into a definitive agreement to amass Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will broaden Dover’s biopharma single-use manufacturing offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue in the course of the full yr 2022.
When the deal closes, Malema will turn into a part of the PSG business unit inside Dover’s Pumps & Process Solutions phase.
“We see an amazing long-term development alternative in the bioprocessing industry driven by a powerful and growing pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as properly as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of extra efficient single-use production processes helps a sturdy outlook for our offerings of single-use elements to end-customers. pressure gauge believe that pairing Malema’s know-how with our present portfolio of single-use pumps for biopharma processing will greatly improve the accuracy and worth proposition of our options to our clients.”
“We are methodically building out our biopharma platform through proactive capacity additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest component technologies,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing know-how and further strengthens our sensor portfolio with new proprietary know-how. In addition to attractive biopharma functions, we expect strong development in the semiconductor space on the capacity growth and re-shoring tailwinds.”
Share